NovoCure Limited (NVCR)

Market Cap	2.19B
Revenue (ttm)	525.66M
Net Income (ttm)	-192.74M
Shares Out	107.61M
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	909.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,315,124
Open	18.19
Previous Close	17.98
Day's Range	18.19 - 20.53
52-Week Range	10.87 - 83.60
Beta	0.49
Analysts	Buy
Price Target	45.67 (+124.75%)
Earnings Date	May 2, 2024

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporate...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,453
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR

Financial Performance

In 2023, NovoCure's revenue was $509.34 million, a decrease of -5.30% compared to the previous year's $537.84 million. Losses were -$207.04 million, 123.7% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $45.67, which is an increase of 124.75% from the latest price.

Price Target

$45.67

(124.75% upside)

Analyst Consensus: Buy